Cited by 181Extracellular vesicles in diseaseRNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation

Open access

Wang, Jing-Hung, Forterre, Alexis V., Zhao, Jinjing, Frimannsson, Daniel O., Delcayre, Alain, Antes, Travis J., Efron, Bradley, Jeffrey, Stefanie S., Pegram, Mark D., Matin, A.C.·2018·Molecular Cancer Therapeutics

DOI 10.1158/1535-7163.mct-17-0827PMC PMC5932266

Published version of a preprint

Open this paper in CoChat — free account

Abstract

This paper deals with specific targeting of the prodrug/enzyme regimen, CNOB/HChrR6, to treat a serious disease, namely HER2+ human breast cancer with minimal off-target toxicity. HChrR6 is an improved bacterial enzyme that converts CNOB into the cytotoxic drug MCHB. Extracellular vesicles (EV) were used for mRNA-based HchrR6 gene delivery: EVs may cause minimal immune rejection, and mRNA may be superior to DNA for gene delivery. To confine HChrR6 generation and CNOB activation to the cancer, the EVHB chimeric protein was constructed. It contains high-affinity anti-HER2 scFv antibody (ML39) and is capable of latching on to EV surface. Cells transfected with EVHB-encoding plasmid generated EVs displaying this protein (“directed EVs”). Transfection of a separate batch of cells with the new plasmid, XPort/HChrR6, generated EVs containing HChrR6 mRNA; incubation with pure EVHB enabled these to target the HER2 receptor, generating “EXO-DEPT” EVs. EXO-DEPT treatment specifically enabled HER2-overexpressing BT474 cells to convert CNOB into MCHB in actinomycin D–independent manner, showing successful and specific delivery of HChrR6 mRNA. EXO-DEPTs—but not undirected EVs—plus CNOB caused near-complete growth arrest of orthotopic BT474 xenografts in vivo, demonstrating for the first time EV-mediated delivery of functional exogenous mRNA to tumors. EXO-DEPTs may be generated from patients' own dendritic cells to evade immune rejection, and without plasmids and their potentially harmful genetic material, raising the prospect of clinical use of this regimen. This approach can be used to treat any disease overexpressing a specific marker. Mol Cancer Ther; 17(5); 1133–42. ©2018 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-17-0827

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
The Phyre2 web portal for protein modeling, prediction and analysis
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., & Sternberg, M. J. E. (2015) · Nature Protocols · doi:10.1038/nprot.2015.053 · Cited by 9,652
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D. J., EIERMANN, W., Robert, N. J., Pieńkowski, T., Martín, M., Press, M. F., Mackey, J. R., Glaspy, J. A., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,833

Show all 67 references

Sorted by citations

Context-specific regulation of extracellular vesicle biogenesis and cargo selection
Dixson, A. C., Dawson, T. R., Vizio, D. D., & Weaver, A. M. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00576-0 · Cited by 847
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking
Murphy, D. E., de Jong, O. G., Brouwer, M., Wood, M. J. A., Lavieu, G., Schiffelers, R. M., & Vader, P. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0223-5 · Cited by 740
Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer
Liang, G., Zhu, Y., Ali, D. J., Tian, T., Xu, H., Si, K., Sun, B., Chen, B., & Xiao, Z. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0563-2 · Cited by 619
Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance
Salunkhe, S. A., Dheeraj, Basak, M., Chitkara, D., & Mittal, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.042 · Cited by 513
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Challenges in Clinical Applications
Gowen, A. M., Shahjin, F., Chand, S., Odegaard, K. E., & Yelamanchili, S. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00149 · Cited by 346
Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display
Antes, T. J., Middleton, R., Luther, K. M., Ijichi, T., Peck, K. A., Liu, W. J., Valle, J., Echavez, A. K., & Marbán, E. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0388-4 · Cited by 261
Self-citation
The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research
Das, S., Abdel‐Mageed, A. B., Adamidi, C., Adelson, P. D., Akat, K. M., Alsop, E. B., Ansel, K. M., Arango, J. I., D, N. A. M., Kilinc, S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.023 · Cited by 223
Self-citation
Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies
de Castilla, P. E. M., Tong, L., Huang, C., Sofias, A. M., Pastorin, G., Chen, X. S., Storm, G., Schiffelers, R. M., & Wang, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.011 · Cited by 219
Self-citation
Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification
Liu, Q., Li, D., Pan, X., & Liang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02081-0 · Cited by 201
Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications
Amiri, A., Bagherifar, R., Ansari Dezfouli, E., Kiaie, S. H., Jafari, R., & Ramezani, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03325-7 · Cited by 186
Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy
Zhuang, J., Tan, J., Wu, C., Zhang, J., Liu, T., Fan, C., Li, J., & Zhang, Y. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa683 · Cited by 180
New advances in exosome-based targeted drug delivery systems
Ferreira, D., Moreira, J. N., & Rodrigues, L. R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103628 · Cited by 180
Exosome for mRNA delivery: Strategies and therapeutic applications
Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., & Zeng, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02634-x · Cited by 144
Systematic review of targeted extracellular vesicles for drug delivery – Considerations on methodological and biological heterogeneity
Gudbergsson, J. M., Jønsson, K., Simonsen, J. B., & Johnsen, K. B. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.006 · Cited by 139
Extracellular vesicle-based Nanotherapeutics: Emerging frontiers in anti-inflammatory therapy
Tang, T., Wang, B., Lv, L., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.47865 · Cited by 137
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Extracellular Vesicles as Natural, Safe and Efficient Drug Delivery Systems
Villa, F., Quarto, R., & Tasso, R. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110557 · Cited by 129
Engineering Exosomes for Therapeutic Applications: Decoding Biogenesis, Content Modification, and Cargo Loading Strategies
Bahadorani, M., Nasiri, M., Dellinger, K., Aravamudhan, S., & Zadegan, R. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s464249 · Cited by 121
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124
A comprehensive review on the composition, biogenesis, purification, and multifunctional role of exosome as delivery vehicles for cancer therapy
Li, J., Zhang, Y., Dong, P.-Y., Yang, G.-M., & Gurunathan, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115087 · Cited by 115
Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope
Aslan, C., Kiaie, S. H., Zolbanin, N. M., Lotfinejad, P., Ramezani, R., Kashanchi, F., & Jafari, R. (2021) · BMC Biotechnology · doi:10.1186/s12896-021-00683-w · Cited by 113
Surface-Engineered Extracellular Vesicles in Cancer Immunotherapy
Johnson, V., Vasu, S., Sukumar, U. K., & Kumar, M. (2023) · Cancers · doi:10.3390/cancers15102838 · Cited by 106
Engineered Extracellular Vesicles as a Reliable Tool in Cancer Nanomedicine
Susa, F., Limongi, T., Dumontel, B., Vighetto, V., & Cauda, V. (2019) · Cancers · doi:10.3390/cancers11121979 · Cited by 103
Extracellular vesicles in cancer nanomedicine
Tarasov, V. V., Svistunov, A. A., Chubarev, V. N., Dostdar, S. A., Sokolov, A. V., Brzecka, A., Sukocheva, O., Neganova, M. E., Klochkov, S. G., Somasundaram, S. G., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.017 · Cited by 97
Exosome-Based Carrier for RNA Delivery: Progress and Challenges
Lu, Y., Huang, W. C., Li, M., & Zheng, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020598 · Cited by 103
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
Genetically encoding multiple functionalities into extracellular vesicles for the targeted delivery of biologics to T cells
Stranford, D. M., Simons, L. M., Berman, K. E., Cheng, L., DiBiase, B. N., Hung, M. E., Lucks, J. B., Hultquist, J. F., & Leonard, J. N. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01142-x · Cited by 94
Current knowledge of hybrid nanoplatforms composed of exosomes and organic/inorganic nanoparticles for disease treatment and cell/tissue imaging
Soltanmohammadi, F., Gharehbaba, A. M., Zangi, A. R., Adibkia, K., & Javadzadeh, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117248 · Cited by 87
Biodistribution of therapeutic extracellular vesicles
Gupta, D., Wiklander, O. P. B., Wood, M. J. A., & Andaloussi, S. E. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.12 · Cited by 82
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Regenerative Potential and Challenges
Fuloria, S., Subramaniyan, V., Dahiya, R., Dahiya, S., Sudhakar, K., Kumari, U., Sathasivam, K. V., Meenakshi, D. U., Wu, Y. S., Sekar, M., et al. (2021) · Biology · doi:10.3390/biology10030172 · Cited by 78
Extracellular vesicles incorporating retrovirus-like capsids for the enhanced packaging and systemic delivery of mRNA into neurons
Gu, W., Luozhong, S., Cai, S., Londhe, K., Elkasri, N., Hawkins, R. D., Yuan, Z., Greene, K. S., Yin, Y., Cruz, M., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01150-x · Cited by 85
The Challenges and Possibilities of Extracellular Vesicles as Therapeutic Vehicles
Melling, G. E., Carollo, E., Conlon, R., Simpson, J. C., & Carter, D. R. F. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.08.009 · Cited by 75
Surface Engineering of Extracellular Vesicles through Chemical and Biological Strategies
Richardson, J. J., & Ejima, H. (2019) · Chemistry of Materials · doi:10.1021/acs.chemmater.9b00050 · Cited by 73
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74
Extracellular vesicle‐based nucleic acid delivery
Lu, M., Shao, W., Xing, H., & Huang, Y. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20220007 · Cited by 75
Extracellular vesicles and oncogenic signaling
Schubert, A., & Boutros, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12855 · Cited by 72
Microvesicle-Mediated Delivery of Minicircle DNA Results in Effective Gene-Directed Enzyme Prodrug Cancer Therapy
Kanada, M., Kim, B. D., Hardy, J. W., Ronald, J. A., Bachmann, M. H., Bernard, M. P., Perez, G. I., Zarea, A. A., Ge, T. J., Withrow, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0299 · Cited by 69
Recent Advances in Extracellular Vesicles as Drug Delivery Systems and Their Potential in Precision Medicine
de Jong, B., Barros, E., Hoenderop, J. G. J., & Rigalli, J. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111006 · Cited by 71
Converting extracellular vesicles into nanomedicine: loading and unloading of cargo
Joshi, B. S., Ortíz-Rios, D., & Zuhorn, I. S. (2021) · Materials Today Nano · doi:10.1016/j.mtnano.2021.100148 · Cited by 71
Engineered extracellular vesicles-like biomimetic nanoparticles as an emerging platform for targeted cancer therapy
Liu, X., Xiao, C., & Xiao, K. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02064-1 · Cited by 74
Extracellular vesicles for the delivery of gene therapy
Ianni, E. D., Obuchi, W., Breyne, K., & Breakefield, X. O. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00277-7 · Cited by 83
Molecular engineering of extracellular vesicles for drug delivery: Strategies, challenges, and perspectives
Dave, K. M., Pinky, P. P., & Manickam, D. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114068 · Cited by 80
Tumor-derived extracellular vesicles in breast cancer: From bench to bedside
Wang, H., & Gires, O. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.012 · Cited by 67
Standardization Approaches for Extracellular Vesicle Loading with Oligonucleotides and Biologics
Roerig, J., & Schulz‐Siegmund, M. (2023) · Small · doi:10.1002/smll.202301763 · Cited by 67
Targeting Senescent Alveolar Epithelial Cells Using Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Pulmonary Fibrosis
Long, Y., Yang, B., Lei, Q., Gao, F., Chen, L., Chen, W., Chen, S., Ren, W., Cao, Y., Xu, L., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c10547 · Cited by 65
Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles
Mai, A., Levy, D. H., Brown, A. K., Marriott, G., & Lü, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-53844-5 · Cited by 64
Extracellular Vesicle–Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity
Forterre, A. V., Wang, J.-H., Delcayre, A., Kim, K., Green, C., Pegram, M. D., Jeffrey, S. S., & Matin, A. C. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0928 · Cited by 62
Self-citation
Transcytosis of Bacillus subtilis extracellular vesicles through an in vitro intestinal epithelial cell model
Rubio, A. P. D., Martínez, J. H., Palavecino, M. D., Fuentes, F., Sánchez‐López, C. M., Marcilla, A., Pérez, O. E., & Piuri, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60077-4 · Cited by 62
New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies
Jayasinghe, M. K., Tan, M., Peng, B., Yang, Y., Sethi, G., Pirisinu, M., & Le, M. T. N. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.010 · Cited by 62
Smart exosomes enhance PDAC targeted therapy
Creeden, J. F., Sevier, J., Zhang, J., Lapitsky, Y., Brunicardi, F. C., Jin, G., Nemunaitis, J. J., Liu, J., Nestor‐Kalinoski, A. L., Rao, D., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.037 · Cited by 62
Exosomes as Potential Functional Nanomaterials for Tissue Engineering
Yao, Y., Jiang, Y., Song, J., Wang, R., Li, Z., Yang, L., Wu, W., Zhang, L., & Peng, Q. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201989 · Cited by 59
Exosomes as Natural Nanocarriers for RNA-Based Therapy and Prophylaxis
Gorshkov, A. N., Purvinsh, L. V., Brodskaia, A. V., & Vasin, A. V. (2022) · Nanomaterials · doi:10.3390/nano12030524 · Cited by 60
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 53
Exploring precision treatments in immune‐mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery
Xu, L., Shao, Z., Fang, X., Xin, Z., Zhao, S., Zhang, H., Zhang, Y., Zheng, W., Yu, X., Zhang, Z., et al. (2024) · Exploration · doi:10.1002/exp.20230165 · Cited by 56
Exosomes in cancer: Small transporters with big functions
Li, X., Wang, Y., Wang, Q., Liu, Y., Bao, W., & Wu, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.037 · Cited by 51
Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis
Brena, D., Huang, M., & Bond, V. C. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101286 · Cited by 51
Extracellular vesicles as carriers of mRNA: Opportunities and challenges in diagnosis and treatment
Kirian, R. D., Steinman, D., Jewell, C. M., & Zierden, H. C. (2024) · Theranostics · doi:10.7150/thno.93115 · Cited by 49
Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies
Safaei, S., Fadaee, M., Farzam, O. R., Yari, A., Poursaei, E., Aslan, C., Samemaleki, S., Shanehbandi, D., Baradaran, B., & Kazemi, T. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01810-z · Cited by 50
Exosome Source Matters: A Comprehensive Review from the Perspective of Diverse Cellular Origins
Chen, Y., Qi, W., Wang, Z., & Niu, F. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020147 · Cited by 54
Upregulation of syncytin-1 promotes invasion and metastasis by activating epithelial-mesenchymal transition-related pathway in endometrial carcinoma
Liu, C., Xu, J., Wen, F., Yang, F., Li, X., Geng, D., Li, L., Chen, J., & Zheng, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s191041 · Cited by 46
CRISPR delivery with extracellular vesicles: Promises and challenges
Berggreen, A. H., Petersen, J. L., Lin, L., Benabdellah, K., & Luo, Y. (2023) · Journal of Extracellular Biology · doi:10.1002/jex2.111 · Cited by 48
Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects
Jahan, S., Mukherjee, S., Ali, S., Bhardwaj, U., Choudhary, R. K., Balakrishnan, S., Naseem, A., Mir, S. A., Banawas, S., Alaidarous, M., et al. (2022) · Cells · doi:10.3390/cells11030490 · Cited by 47
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders
Lü, B., Ku, J., Flojo, R. A. B., Olson, C., Bengford, D., & Marriott, G. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114465 · Cited by 47
Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges
Du, R., Wang, C., Zhu, L., & Yang, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102236 · Cited by 45
Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery
Saux, S. L., Aubert‐Pouëssel, A., Mohamed, K. E., Martineau, P., Guglielmi, L., Devoisselle, J., Legrand, P., Chopineau, J., & Morille, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113837 · Cited by 48
Targeting Capabilities of Native and Bioengineered Extracellular Vesicles for Drug Delivery
Frolova, L., & Li, I. T. S. (2022) · Bioengineering · doi:10.3390/bioengineering9100496 · Cited by 43
Basic Guide for Approaching Drug Delivery with Extracellular Vesicles
Brezgin, S., Danilik, O., Yudaeva, A., Kachanov, A., Kostyusheva, A., Karandashov, I., Ponomareva, N., Zamyatnin, A. A., Parodi, A., Chulanov, V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910401 · Cited by 48
Bioinspired cellular membrane-derived vesicles for mRNA delivery
Xu, X., Xu, L., Wang, J., Wen, C., Xia, J., Zhang, Y., & Liang, Y. (2024) · Theranostics · doi:10.7150/thno.93755 · Cited by 43
Self-citation
Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines
Li, Q., Xing, H., Naeem, A., Zhang, K., Zheng, A., Huang, Y., & Lu, M. (2025) · Exploration · doi:10.1002/exp.20240109 · Cited by 44
Hydrogels loaded with MSC‐derived small extracellular vesicles: A novel cell‐free tissue engineering system for diabetic wound management
Zhong, W., Meng, H., Ma, L., Wan, X., Chen, S., Ma, K., Lu, L., Su, J., Guo, K., Jiang, Y., et al. (2024) · Open Research (University of Surrey) · doi:10.1002/viw.20230110 · Cited by 42
Cytochalasin-B-Inducible Nanovesicle Mimics of Natural Extracellular Vesicles That Are Capable of Nucleic Acid Transfer
Oshchepkova, A. L., Neumestova, A. I., Матвеева, В. А., Artemyeva, L., Morozova, K. N., Владимировна, К. Е., Аркадьевна, З. М., & Vlassov, V. V. (2019) · Micromachines · doi:10.3390/mi10110750 · Cited by 39
Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles
Huang, X., Li, A., Xu, P., Yu, Y., Li, S., Hu, L., & Feng, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01952-w · Cited by 43
Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy
Zocchi, M. R., Tosetti, F., Benelli, R., & Poggi, A. D. (2020) · Cancers · doi:10.3390/cancers12071886 · Cited by 35
Perspectives in Manipulating EVs for Therapeutic Applications: Focus on Cancer Treatment
Nazimek, K., & Bryniarski, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134623 · Cited by 34
Engineering Extracellular Vesicles to Target Pancreatic Tissue In Vivo
Komuro, H., Kawai‐Harada, Y., Aminova, S., Pascual, N., Malik, A., Contag, C. H., & Harada, M. (2021) · Nanotheranostics · doi:10.7150/ntno.54879 · Cited by 34
Extracellular Vesicles as Drug Delivery System for Cancer Therapy
Wang, J., Yin, B., Lian, J., & Wang, X. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081029 · Cited by 33
Self-citation
Extracellular Vesicles Tropism: A Comparative Study between Passive Innate Tropism and the Active Engineered Targeting Capability of Lymphocyte-Derived EVs
Limongi, T., Susa, F., Dumontel, B., Racca, L., Donnorso, M. P., Debellis, D., & Cauda, V. (2021) · Membranes · doi:10.3390/membranes11110886 · Cited by 31
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Extracellular vesicle-mediated nucleic acid transfer and reprogramming in the tumor microenvironment
Parayath, N. N., Padmakumar, S., & Amiji, M. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.009 · Cited by 31
An engineered CD81‐based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles
Vogt, S., Bobbili, M. R., Stadlmayr, G., Stadlbauer, K., Kjems, J., Rüker, F., Grillari, J., & Wozniak‐Knopp, G. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12139 · Cited by 30
Exosome-based delivery nanoplatforms: next-generation theranostic platforms for breast cancer
Zheng, Y., Li, M., Weng, B., Mao, H., & Zhao, J. (2022) · Biomaterials Science · doi:10.1039/d2bm00062h · Cited by 30
Self-citation
Direct Modification of Extracellular Vesicles and Its Applications for Cancer Therapy: A Mini-Review
Nan, W., Zhang, C., Wang, H., Chen, H., & Ji, S. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.910341 · Cited by 33
Biomolecular corona potential in extracellular vesicle engineering for therapeutic applications
Esmaeili, A., Eslaminejad, M. B., & Hosseini, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118202 · Cited by 32
Extracellular Vesicles for Therapeutic Nucleic Acid Delivery: Loading Strategies and Challenges
Oshchepkova, A. L., Аркадьевна, З. М., & Vlassov, V. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087287 · Cited by 35
mRNA-based therapeutic strategies for cancer treatment
Taibi, T., Cheon, S., Perna, F., & Vu, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.035 · Cited by 31
Emerging Strategies for Cargo Loading and Engineering of Extracellular Vesicles for Breast Cancer Treatment
Mediratta, K., Diab, M. D., Han, P., Hu, H., & Wang, L. (2025) · Nanomaterials · doi:10.3390/nano15181418 · Cited by 29
Multifunctional Applications of Engineered Extracellular Vesicles in the Treatment of Cancer
Kugeratski, F. G., McAndrews, K. M., & Kalluri, R. (2021) · Endocrinology · doi:10.1210/endocr/bqaa250 · Cited by 27
Genetically Engineered Extracellular Vesicles Harboring Transmembrane Scaffolds Exhibit Differences in Their Size, Expression Levels of Specific Surface Markers and Cell-Uptake
Zhang, J., Brown, A. K., Johnson, B., Diebold, D., Asano, K., Marriott, G., & Lü, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122564 · Cited by 32
Developing mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 33
Self-citation
Reprogramming extracellular vesicles with engineered proteins
Shi, X., Cheng, Q., & Zhang, Y. (2019) · Methods · doi:10.1016/j.ymeth.2019.09.017 · Cited by 26
Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies
Allegra, A., Petrarca, C., Gioacchino, M. D., Casciaro, M., Musolino, C., & Gangemi, S. (2022) · Cells · doi:10.3390/cells11071128 · Cited by 26
Engineered exosomes for tissue regeneration: from biouptake, functionalization and biosafety to applications
Zhang, M., Wan, L., Li, R., Li, X., Zhu, T., & Lu, H. (2023) · Biomaterials Science · doi:10.1039/d3bm01169k · Cited by 26
Extracellular vesicles derived from mesenchymal stem cells: the wine in Hebe's hands to treat skin aging
Gui, Q., Ding, N., Yao, Z., Wu, M., Fu, R., Wang, Y., Zhao, Y., & Zhu, L. (2024) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbae004 · Cited by 27
The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells
Ferrantelli, F., Arenaccio, C., Manfredi, F., Olivetta, E., Chiozzini, C., Leone, P., Percario, Z. A., Ascione, A., Flego, M., Bonito, P. D., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s209366 · Cited by 26
Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy
Tang, Y., Liu, X., Sun, M., Xiong, S., Xiao, N., Li, J., He, X., & Xie, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071902 · Cited by 24
Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories
González, Á., López-Borrego, S., Sandúa, A., Valés‐Gómez, M., & Alegre, E. (2024) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2024.2309935 · Cited by 27
Exosome vesicle as a nano-therapeutic carrier for breast cancer
Mughees, M., Kumar, K., & Wajid, S. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1808001 · Cited by 24

Authors: Wang, J.-H., Forterre, A. V., Zhao, J., Frimannsson, D. O., Delcayre, A., Antes, T. J., Efron, B., Jeffrey, S. S., Pegram, M. D., & Matin, A. C.
Affiliations: Stanford Medicine (US)
2ExoThera LLC, Menlo Park, California.
System Biosciences (United States) (US)
Stanford University (US)
Corresponding author: Matin, A.C.
ORCID: Forterre, Alexis V.
Frimannsson, Daniel O.
Antes, Travis J.
Jeffrey, Stefanie S.
Pegram, Mark D.
Matin, A.C.
Venue: Molecular Cancer Therapeutics
Publisher: American Association for Cancer Research (AACR)
Published: 2018-04-30
Volume: 17
Issue: 5
Pages: 1133-1142
ISSN: 1535-7163 (ISSN-L)
1538-8514
DOI: 10.1158/1535-7163.mct-17-0827
PMC: PMC5932266
OpenAlex: W2792159629
Cited by: 181
References: 67
Citations by year: 2026: 12 · 2025: 28 · 2024: 33 · 2023: 29 · 2022: 26 · 2021: 17 · 2020: 16 · 2019: 15 · 2018: 5
FWCI: 4.71
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Molecular Cancer Therapeutics (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: NIH (UH3TR000902)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords: HER2-positive breast cancer, extracellular vesicles, prodrug activation, fusion protein, targeted drug delivery, BT474 xenograft, tumor growth inhibition
MeSH terms: Extracellular Vesicles, Animals, Breast Neoplasms, Female, Humans, Mice, Inbred BALB C, Mice, Nude, Oxazines, Prodrugs, RNA, Messenger, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Single-Chain Antibodies, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks